论文信息 - Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program. - 字舞流文

Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.

J. Roberts | S. Wallis | A. Stewart | A. Allworth | K. McCarthy | A. Legg

[1] Christopher M. Bland,et al. Use of Continuous-Infusion Ceftolozane/Tazobactam in a Multidrug-Resistant Pseudomonas aeruginosa Urinary Tract Infection in the Outpatient Setting , 2017, The Annals of pharmacotherapy.

[2] Elizabeth G. Rhee,et al. Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps , 2017, Current therapeutic research, clinical and experimental.

[3] M. Mahoney,et al. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. , 2015, International journal of antimicrobial agents.

[4] D. Nicolau,et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia , 2015, Journal of clinical pharmacology.